stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Revenue growth
Ionis Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 June 2026 was −7.41%, down 41.2 percentage points from fiscal 2025 (33.8%). Over the past ten years it has ranged from −35.0% (fiscal 2020) to 87.2% (fiscal 2019); the current reading is higher than 73% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 33.8% | 44.31 |
| FY2024 | −10.5% | (44.58) |
| FY2023 | 34.1% | 61.63 |
| FY2022 | −27.5% | (38.66) |
| FY2021 | 11.1% | 46.17 |
| FY2020 | −35.0% | (122.24) |
| FY2019 | 87.2% | 70.57 |
| FY2018 | 16.6% | (21.30) |
| FY2017 | 37.9% | 6.53 |
| FY2016 | 31.4% | (1.07) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −40.7% | (127.71) |
| Mar 2026 | 87.0% | 97.24 |
| Dec 2025 | −10.3% | (27.38) |
| Sep 2025 | 17.1% | (83.57) |
| 42 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| CGON CG Oncology, Inc. compare | 840.8% |
| AXSM Axsome Therapeutics, Inc. compare | 54.2% |
| MIRM Mirum Pharmaceuticals, Inc. compare | 42.2% |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.03% |
| IONS Ionis Pharmaceuticals, Inc. | −7.41% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| IMVT Immunovant, Inc. compare | — |
| ORKA Oruka Therapeutics, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement